Cannabinoid market forecast at over $700 million
With four drugs now in the marketplace (a 100% rise from two years ago), the cannabinoid market continues to grow, says a new report from Visiongain, which values the market for such drugs at $709.5 million at present, up from $386.7 million in 2006. Attitudes to the drugs are changing ensuring greater market penetration, and the first cannabinoid blockbuster is now a certainty.
The four drugs already available are: Marinol (dronabinol from Solvay); nabilone; Sativex (a cannabis-based oromuscosal spray from GW Pharma) rimonabant (Sanofi-Aventis' Acomplia brand for obesity)
With indications for the control of chemotherapy-induced nausea and vomiting, Marinol has additional approval as an appetite stimulant to treat anorexia associated with HIV/AIDS.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze